Canine osteosarcoma. Amputation and chemoimmunotherapy

Veterinary Clinics of North America - Small Animal Practice

Volumn 26, Issue 1, 1996, Pages 123-133

  MacEwen, E G ^a   Kurzman, I D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CISPLATIN; LIPOSOME; MURAMYL TRIPEPTIDE;

AMPUTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DOG; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NONHUMAN; OSTEOSARCOMA; REVIEW; SURVIVAL TIME;

CANIS FAMILIARIS;

EID: 0030023850     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0195-5616(96)50011-2     Document Type: Review

References (50)

1. J. Berg M.J. Weinsteiri D.S. Springfield Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma J Am Vet Med Assoc 206 1995 1555
2. P.J. Bergman E.G. MacEwen I.D. Kurzman Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991–1993) J Vet Intern Med 1995
3. J. Bezault C. Walsh L. Tarcsay Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs In Vivo 7 1993 487
4. R.S. Brodey The use of naturally occurring cancer in domestic animals for research into human cancer: General considerations and a review of canine skeletal osteosarcoma Yale J Biol Med 52 1979 345
5. + monocyte population in patients recovering from myelosuppressive chemotherapy Proceedings of the American Society of Hematology 1993
6. I.J. Fidler Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine Cancer Immunol Immunother 21 1986 169
7. I.J. Fidler C.M. Balch The biology of cancer metastasis and implications for therapy Curr Probl Surg 27 1987 131
8. I.J. Fidler E.S. Kleinerman Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under co-cultivation conditions J Clin Oncol 2 1987 937
9. I.J. Fidler G. Poste Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease Springer Semin Immunopathol 5 1982 161
10. I.J. Fidler A.J. Schroit Recognition and destruction of neoplastic cells by activated macrophages: Discrimination of altered self Biochim Biophys Acta 948 1988 151
11. I.J. Fidler Z. Barnes W.E. Fogler Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators Cancer Res 42 1982 496
12. I.J. Fidler W.E. Fogler L. Tarcsay Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hydrophilic or lipophilic muramyl dipeptide Advances in Immunopharmacology 2 1983 235
13. W.E. Fogler I.J. Fidler Modulation of the immune response by muramyl dipeptide M.A. Chirigos R.L. Fenichel Immune Modulations Agents and Their Mechanisms 1984 Marcel Dekker New York 499
14. J.B. Hibbs Jr. Discrimination between neoplastic and non-neoplastic cells by in vitro activated macrophages J Natl Cancer Inst 53 1974 1487
15. W.G. Hocking D.W. Golde The pulmonary-alveolar macrophage, Part I N Engl J Med 301 1979 580
16. S.F. Jia J. Garro N. Jaffe Ifosfamide does not inhibit monocyte activation by liposomal muramyl tripeptide Proceedings of the Annual Meeting of the American Association of Cancer Research, Orlando, FL 1993 1336
17. F. Kimura Y. Takemura T. Ohtsuki Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy Int J Hematol 55 1992 147
18. E.S. Kleinerman J.S. Snyder N. Jaffe Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with sarcoma J Clin Oncol 9 1991 259
19. E.S. Kleinerman J.B. Gano D.A. Johnston Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma Am J Clin Oncol 18 1995 93
20. E.S. Kleinerman F.S. Jia J. Griffin Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration J Clin Oncol 10 1992 1310
21. E.S. Kleinerman A.K. Raymond C.D. Bucana Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A Lipid) Cancer Immunol Immunother 34 1992 211
22. E.S. Kleinerman A.J. Schroit W.E. Fogler Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines J Clin Invest 72 1983 304
23. I.D. Kurzman F. Shi E.G. MacEwen In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide J Vet Immunol Immunopathol 38 1993 45
24. I.D. Kurzman E.G. MacEwen R.R. Dubielzig Cisplatin and L-MTP-PE combination therapy for osteosarcoma Proceedings of the 14th Annual Veterinary Cancer Society Conference, Tennessee 1994 105
25. Kurzman ID, MacEwen EG, Rosenthal RC, et al: Adjuvant therapy for osteosarcoma in dogs: Results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clinical Cancer Research (in press).
26. S.M. LaRue S.J. Withrow Tumors of the skeletal system S.J. Withrow E.G. MacEwen Clinical Veterinary Oncology 1989 JB Lippincott Philadelphia 234
27. E.G. MacEwen Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment Cancer Metastasis Rev 9 1990 125
28. E.G. MacEwen I.D. Kurzman S. Helfand Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: A progress review Journal of Drug Targeting 2 1994 391
29. E.G. MacEwen I.D. Kurzman R.C. Rosenthal Combined liposome-encapsulated muramyl tripeptide and cisplatin in dogs with osteosarcoma J.D. Novak J.H. McMaster Frontiers of Osteosarcoma Research 1993 Hogrefe and Huber Seattle 117
30. E.G. MacEwen I.D. Kurzman R.C. Rosenthal Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide J Natl Cancer Inst 81 1989 935
31. M. Maeda R.D. Knowles E.S. Kleinerman Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro Cancer Communications 3 10–11 1991 313
32. G.N. Mauldin R.E. Matus S.J. Withrow Canine osteosarcoma: Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin J Vet Intern Med 2 1988 177
33. J.A. Meyer R.T. Dueland E.G. MacEwen Canine osteogenic sarcoma treated by amputation and MER: An adverse effect of splenectomy on survival Cancer 49 1982 1613
34. D.H. Munn A.C. Beall H. Sabio Recombinant macrophage colony-stimulating factor in non-human primates: Selective expansion of a novel monocyte subset (abstract) Blood 82 suppl 1993 434
35. L.N. Owen D.E. Bostock R.B. Lavelle Studies on chemotherapy and immunotherapy in canine lymphosarcoma and osteosarcoma Bibl-Haematol 43 1975 522
36. L.N. Owen D.E. Bostock R.B. Lavelle Study on therapy of osteosarcoma in dogs using BCG vaccine J Amer Radiol 18 1977 27
37. B. Passlick D. Flieger H.W.L. Ziegler-Heitbrock Identification and characterization of a novel monocyte subpopulation in human peripheral blood Blood 74 1989 2527
38. I. Saiki I.J. Fidler Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages J Immunol 135 1985 684
39. W. Shapiro T.W. Fossum B.E. Kitchell Use of cisplatin for the treatment of appendicular osteosarcoma in dogs J Am Vet Med Assoc 4 1988 507
40. F. Shi I.D. Kurzman E.G. MacEwen Interleukin-6 induction by liposome-encapsulated muramyl tripeptide in normal dogs Proceedings of the Veterinary Cancer Society Conference, Ohio 1993 73
41. Shi F, Kurzman ID, MacEwen EG: In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs. Am J Vet Res (submitted).
42. F. Shi E.G. MacEwen I.D. Kurzman In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation Cancer Res 53 1993 3986
43. B.W. Smith I.D. Kurzman K.T. Schultz Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells Cancer Biotherapy 8 1993 137
44. R.C. Straw S.J. Withrow S.L. Richter Amputation and cisplatin for treatment of canine osteosarcoma J Vet Intern Med 6 1992 205
45. E.D. Thomas R.E. Ramberg G.E. Sale Direct evidence for a bone marrow origin of the alveolar macrophage in man Science 192 1976 1016
46. J.P. Thompson M.J. Fugent Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990) J Am Vet Med Assoc 200 1992 531
47. R. VanFurth Phagocytic cells: Development and distribution of mononuclear phagocytes in normal steady state and inflammation I.M. Goldstein R. Snyderman Inflammation; Basic Principles and Clinical Correlates 1988 Raven Press New York 198 218
48. + macrophages in antitumor cytotoxicity Lab Invest 67 1992 166
49. P.L. Weiden R. Storb M.-S. Tsoi Canine osteosarcoma: Results of amputation with and without adjuvant immunotherapy Cancer Immunol Immunother 5 1978 181
50. S.J. Withrow B.E. Powers R.C. Straw Comparative aspects of osteosarcoma: Dog versus man Clin Orthop 270 1991 159